Empowering Caregivers Message Boards
  News Updates-Caregiving, Health Issues, Legislation & More
  New AIDS Drug Raises Hopes, Fears

Post New Topic  Post A Reply
profile | register | preferences | faq | search

UBBFriend: Email This Page to Someone! next newest topic | next oldest topic
Author Topic:   New AIDS Drug Raises Hopes, Fears
GRM4LOVE
Moderator
posted 08-22-2002 09:39 PM     Click Here to See the Profile for GRM4LOVE     Edit/Delete Message
New AIDS Drug Raises Hopes, Fears
August 22, 2002
NEW YORK (AP) -- The federal government has approved tests of an experimental and potentially expensive AIDS drug that could prolong the lives of patients with drug-resistant strains of HIV.

Dubbed Fuzeon by its developers, Roche Group and Trimeris Inc., the drug won a priority, six-month review from the Food and Drug Administration. The companies hope to put Fuzeon on the market by spring.

"Everyone is so pleased about the drug itself," said Martin Delaney, founding director of Project Inform, an advocacy organization. "It is such a significant development. But we are terribly apprehensive about the cost."

Roche, based in Switzerland, and Trimeris, of Durham, N.C., won't discuss pricing details until the drug is approved, but say Fuzeon is complicated to produce and will be expensive. Experts predict a cost of $10,000 to $15,000 a year per patient.

The most expensive AIDS drugs now available cost about $7,500 a year, although some combination treatments approach $15,000 in annual costs.

Fuzeon's cost should be kept in perspective, said Dr. James Thommes, the drug's medical director at Roche, saying that it keeps people from expensive hospital stays and prolongs their lives.

"No one wants drug companies to stop looking at ways to treat AIDS" because of expense issues, he said.

Cash-strapped AIDS assistance programs are already worried they might not be able to afford Fuzeon. Roche and Trimeris also have said they may not be able to make enough Fuzeon to meet initial demand.

The drug is the first in a class known as fusion inhibitors, which are designed to block HIV from entering blood cells. It acts on the third stage of that entry process, known as fusion.

IP: 66.108.75.139

All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | Empowering Caregivers

EMPOWERING CAREGIVERS´┐Ż is trademarked. All Information on this website is under the umbrella of National Organization For Empowering Caregivers, INC.This includes but is not limited to the journal exercises, Newsletters and original articles, etc. Permission must be obtained from NOFEC by emailing info@nofec.org or telephoning 212.807.1204 for any external use of this material.

Powered by Infopop www.infopop.com © 2000
Ultimate Bulletin Board 5.47e